- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01060293
Dopamine in Acute Decompensated Heart Failure II (DAD-HF II)
September 10, 2013 updated by: Gregory Giamouzis, Larissa University Hospital
Comparison of High-dose Furosemide, Low-dose Furosemide, and the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure
The aim of this study is to compare the effects of 1) high-dose furosemide, 2) low-dose furosemide, and 3) low-dose furosemide combined with low-dose dopamine on diuresis, clinical status, renal function, electrolyte balance, length of stay, and 60-day post-discharge outcomes in patients hospitalized with acute decompensated heart failure.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to compare the effects of:
- high-dose furosemide (HDF, 40 mg furosemide bolus IV, followed by continuous IV infusion of 20 mg/h for a total of 8 hours),
- low-dose furosemide (LDF, 40 mg furosemide bolus IV, followed by continuous IV infusion of 5 mg/h furosemide for a total of 8 hours), and
- low-dose furosemide combined with low-dose dopamine (LDFD, 40 mg furosemide bolus IV, followed by continuous IV infusion of 5 mg/h furosemide plus 5μg/kg/min dopamine for a total of 8 hours) on diuresis, perceived dyspnea, renal function, electrolyte balance, total length of stay, and 60-day post-discharge outcomes in patients hospitalized with ADHF.
Study Type
Interventional
Enrollment (Actual)
161
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Larissa, Greece, 411 10
- Department of Cardiology, Larissa University Hospital
-
Thessaloniki, Greece
- Ahepa University Hospital
-
-
Attiki
-
Athens, Attiki, Greece
- First Department of Cardiology, University of Athens
-
-
Magnesia
-
Volos, Magnesia, Greece, 382 21
- Department of Cardiology, Volos General Hospital
-
-
-
-
Georgia
-
Atlanta, Georgia, United States
- Division of Cardiology, Emory University Hospital
-
-
Ohio
-
Cleveland, Ohio, United States
- The Cleveland Clinic Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with New York Heart Association (NYHA) functional class IV heart failure according to the American Heart Association (AHA) classification, namely dyspnea on minimal exertion or rest dyspnea, orthopnea, and paroxysmal nocturnal dyspnea,
- signs of congestion (third heart sound or pulmonary rales on physical examination),
- pulmonary congestion on chest x-ray,
- serum B-type natriuretic peptide levels > 400 pg/ml or NT-proBNP > 1500 pg/ml,
- echocardiographic documentation of systolic or diastolic dysfunction,
- age >18 years old,
- on medical therapy with an ACE-inhibitor and/or a β-blocker,
- experiencing an acute decompensation of known chronic HF,
- baseline oxygen saturation <90% on admission arterial blood gas
Exclusion Criteria:
- acute de novo HF;
- severe renal failure (serum creatinine >200 μmol/L or GFR <30 ml/min/1.73m2)
- admission systolic blood pressure <90 mm Hg;
- severe valvular disease;
- known adverse reactions to furosemide or dopamine;
- HF secondary to congenital heart disease;
- a scheduled procedure with a need for IV contrast dye;
- a scheduled cardiac surgery within 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: High-dose furosemide
High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
|
High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
|
Active Comparator: Low-dose furosemide
Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
|
Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
|
Active Comparator: Low-dose furosemide combined with low-dose dopamine
Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
|
Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).
Time Frame: 1-year
|
1-year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).
Time Frame: 60-day post discharge
|
60-day post discharge
|
Novel indices of acute renal ischemia/injury (cystatin-C, KIM-1, NGAL)
Time Frame: Throughout hospitalization
|
Throughout hospitalization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Gregory Giamouzis, MD, Department of Cardiology, Larissa University Hospital, Larissa, Greece
- Study Chair: Filippos Triposkiadis, MD, Department of Cardiology, Larissa University Hospital, Larissa, Greece
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Anticipated)
December 1, 2013
Study Completion (Anticipated)
December 1, 2013
Study Registration Dates
First Submitted
February 1, 2010
First Submitted That Met QC Criteria
February 1, 2010
First Posted (Estimate)
February 2, 2010
Study Record Updates
Last Update Posted (Estimate)
September 11, 2013
Last Update Submitted That Met QC Criteria
September 10, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Natriuretic Agents
- Cardiotonic Agents
- Membrane Transport Modulators
- Dopamine Agents
- Diuretics
- Sympathomimetics
- Sodium Potassium Chloride Symporter Inhibitors
- Furosemide
- Dopamine
Other Study ID Numbers
- 3975
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Decompensated Heart Failure
-
Medical University of WarsawMedical University of Graz; Medical University of Vienna; Poznan University of... and other collaboratorsRecruitingAcute Decompensated Heart FailurePoland
-
Yooyoung Pharmaceutical Co., Ltd.RecruitingAcute Decompensated Heart FailureKorea, Republic of
-
Cardionomic Inc.Completed
-
Scripps HealthWithdrawnAcute Decompensated Heart FailureUnited States
-
Christian SchulzeBoehringer Ingelheim; Zentrum für Klinische Studien JenaCompletedAcute Decompensated Heart FailureGermany
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)CompletedAcute Decompensated Heart FailureUnited States
-
Prof. Dr. Jörg LeuppiCompletedAcute Decompensated Heart FailureSwitzerland
-
Byung-Hee OhNational Institute of Health, KoreaCompletedAcute Decompensated Heart FailureKorea, Republic of
-
Trevena Inc.CompletedAcute Decompensated Heart FailureUnited States, Bulgaria, Poland, Russian Federation, Germany, Romania, Argentina, Canada, Czechia, Hungary, Israel, Slovakia
-
University of North Carolina, Chapel HillUniversity of Illinois at Chicago; Virginia Commonwealth UniversityTerminatedAcute Decompensated Heart FailureUnited States
Clinical Trials on High-dose furosemide
-
Jan Kochanowski UniversityRecruiting
-
Beijing Northland Biotech. Co., Ltd.CompletedAcute Myocardial InfarctionChina
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; University of Alabama at Birmingham; Icahn School of Medicine at Mount Sinai and other collaboratorsCompletedEnd Stage Renal DiseaseUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Baylor College of MedicineNeuroMetrix, Inc.RecruitingPain | Neuropathy | Chemotherapy-induced Peripheral NeuropathyUnited States
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...RecruitingSystemic Lupus ErythematosusUnited States, Spain, China, Korea, Republic of, Argentina, Bulgaria, Chile, Greece, Japan, Mauritius, Mexico, Moldova, Republic of, Poland, South Africa, Australia, Colombia, Philippines, Serbia
-
Jiangsu Kanion Pharmaceutical Co., LtdCompleted
-
Purdue UniversityAlliance for Potato Research and EducationCompletedBlood Pressure | Potassium BioavailabilityUnited States
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States